CagriSema Explained: How the Amylin + GLP-1 Combination Works

The two-compound combination, decoded

CagriSema is the working name for Novo Nordisk's fixed-ratio combination of two molecules: cagrilintide (a long-acting amylin analog) and semaglutide (the GLP-1 receptor agonist marketed as Wegovy for obesity and Ozempic for diabetes). The two compounds are co-formulated in a single weekly subcutaneous injection — much like how tirzepatide combines GIP and GLP-1 activity in one molecule, except that here the two activities come from two separate peptides administered together.

This matters because amylin is a pathway distinct from GLP-1 and GIP, the two receptor systems that dominate current incretin pharmacology. The CagriSema bet is that adding amylin signaling to GLP-1 signaling produces meaningfully greater weight loss than either pathway alone — and the REIMAGINE 1 Phase 3 data is the first large-trial confirmation that this is true.

The amylin axis: a different kind of satiety

Amylin is a 37-amino-acid peptide hormone secreted by pancreatic beta cells, co-released with insulin in response to meals. It does several things that GLP-1 doesn't directly do:

• Slows gastric emptying through a different mechanism than GLP-1's vagal pathway — amylin acts on receptors in the area postrema and other central sites, producing satiety signals via a partially separate neural circuit.
• Suppresses postprandial glucagon — reducing the glucagon-driven hepatic glucose production that contributes to post-meal blood glucose elevation.
• Promotes satiety via direct central action on amylin receptors in the hypothalamus and brainstem — receptors that don't substantially overlap with GLP-1 receptor expression patterns.
• Reduces food intake and body weight in preclinical and human studies, with effects that are additive to GLP-1-mediated weight loss rather than redundant.

Natural amylin has a very short half-life and pH-dependent solubility that makes it difficult to use therapeutically. Pramlintide (Symlin), the synthetic analog that's been approved for diabetes since 2005, requires multiple daily injections and has substantial GI side-effect tolerability issues that have limited its use. Cagrilintide is the new generation — a long-acting amylin analog with weekly dosing, better tolerability, and the receptor-binding profile suitable for combination with weekly GLP-1 agonists. See our cagrilintide peptide page and the CagriSema peptide page for the underlying pharmacology in detail.

REIMAGINE 1: the Phase 3 readout that confirmed the hypothesis

REIMAGINE 1 is the lead Phase 3 trial in the broader REDEFINE program — Novo Nordisk's clinical-development plan for CagriSema in obesity. The trial published in The Lancet in 2026 provides the first large randomized comparison of the combination against semaglutide monotherapy at therapeutic doses, in a population large enough to characterize both efficacy and safety with confidence.

The headline efficacy findings:

• Mean weight loss at 68 weeks: approximately 22.7% on CagriSema vs 15.6% on semaglutide 2.4 mg vs 2.3% on placebo — a roughly 7-percentage-point advantage for the combination over semaglutide alone, beyond what either compound produces in isolation.
• Proportion of patients losing ≥20% body weight: approximately 60% on CagriSema vs 32% on semaglutide alone — a near-doubling of the high-responder rate.
• Glycemic effects in participants with prediabetes or baseline metabolic dysfunction were similarly strong, with substantial reductions in HbA1c and fasting glucose.
• Cardiovascular biomarkers (blood pressure, lipid profile, inflammatory markers) all improved meaningfully on CagriSema, broadly tracking the magnitude of weight loss.

For context, the trial-tested CagriSema dose is 2.4 mg semaglutide plus 2.4 mg cagrilintide weekly — essentially the same semaglutide dose that produces 15% in monotherapy plus an equivalent dose of the amylin analog. The fact that the combination produces 22% (vs 15% alone) at the same semaglutide dose is what makes this an "additive" rather than "potentiating" finding — the amylin arm contributes its own approximately 7-percentage-point effect on top of what GLP-1 alone does.

What this means for the broader weight-loss landscape

The CagriSema readout has implications across three dimensions of the obesity-pharmacology space:

1. The "single vs combination" question is largely settled in favor of combinations. Both tirzepatide (GIP + GLP-1 in one molecule) and now CagriSema (amylin + GLP-1 in two molecules) demonstrate that hitting multiple satiety pathways produces deeper weight loss than activating GLP-1 alone. The mechanistic logic is robust enough that future development will increasingly target combinations rather than single-pathway monotherapy.

2. The amylin axis is now validated as a clinical-grade weight-loss target. Before REIMAGINE 1, the amylin literature was mostly preclinical and small-trial human data plus the pramlintide experience in diabetes. Cagrilintide's standalone weight-loss signal (~12% monotherapy in Phase 3) and the additive CagriSema effect together establish amylin as a real alternative-pathway target. Several other companies have amylin programs that benefit from this validation — including AstraZeneca's selective amylin agonists in earlier-stage development.

3. The next-generation comparison is now CagriSema vs retatrutide. Retatrutide (triple GIP/GLP-1/glucagon agonist in one molecule) is producing weight-loss numbers in the same magnitude range — ~24-28% across Phase 2 and emerging Phase 3 data. The two represent fundamentally different bets on which receptor combination produces the best obesity therapy: amylin + GLP-1 (CagriSema) vs triple-incretin (retatrutide). The market will likely accommodate both, but the head-to-head comparisons over 2027-2028 will refine which patient profile fits which combination.

How CagriSema differs from semaglutide alone

For users currently on or considering semaglutide therapy, the practical question is what changes with CagriSema beyond simply "more weight loss":

Greater appetite suppression depth and persistence. Users on CagriSema in the trial cohorts reported more sustained satiety effects, with less of the "food noise returning at the end of the dosing interval" pattern that's characteristic of higher-dose semaglutide. The amylin arm appears to flatten the satiety effect across the week rather than concentrating it in the first few days post-injection.

Better glycemic control in patients with metabolic dysfunction. The amylin contribution to postprandial glucagon suppression produces meaningful additive glycemic benefit beyond what GLP-1 alone delivers — particularly relevant for patients with prediabetes or insulin resistance who haven't yet developed full T2D.

Different side-effect profile. CagriSema's tolerability is broadly similar to higher-dose semaglutide on GI side effects — nausea, constipation, diarrhea remain the dominant tolerability concerns. The amylin arm contributes some specific effects (mild taste changes, occasional injection-site reactions) but doesn't dramatically expand the side-effect footprint.

Same hair-loss and lean-mass considerations as other GLP-1 therapies. The biology that drives hair loss on GLP-1 medications (rapid weight loss producing telogen effluvium) and lean-mass loss applies equally to CagriSema. Greater weight loss magnitude means greater attention to nutritional and resistance-training support is appropriate.

Regulatory timeline and access

Based on the REIMAGINE 1 readout and the broader REDEFINE program data, Novo Nordisk is expected to submit a regulatory dossier for CagriSema approval in late 2026, with FDA action anticipated in 2027. Clinical availability through standard pharmacy channels would follow approval, with insurance coverage decisions playing out over 2027-2028.

Until then, CagriSema is not commercially available through standard channels. The combination has been accessible through:

• Clinical trial enrollment (REDEFINE program sites)
• Mexican and other international markets where regulatory frameworks differ from US/EU
• Compounding-pharmacy and grey-market sources (with the identity, purity, and regulatory considerations that come with those routes)

For users currently on semaglutide and curious about CagriSema, the practical recommendation is to continue current therapy and reassess when CagriSema becomes formally available. The marginal benefit of grey-market combination experimentation versus established monotherapy in the meantime is generally not favorable on a risk-adjusted basis.

The combination question: tesofensine, retatrutide, and beyond

CagriSema's validation of "amylin + GLP-1" as a combination strategy opens a substantial design space for further combinations. Several being discussed:

• CagriSema + central appetite agents — our Tesofensine + CagriSema stack page walks through the rationale for adding the central monoamine pathway on top of CagriSema's peripheral GLP-1 and amylin coverage.
• CagriSema vs retatrutide — head-to-head comparison is the most-anticipated 2027-2028 study in obesity pharmacology. Different combinations of receptor coverage producing similar weight-loss magnitudes raises the question of which mechanism profile better fits which patient.
• Multiple-mechanism stacks — community discussion has begun on adding tesofensine, certain mitochondrial peptides, or muscle-preservation agents (bimagrumab-class) to CagriSema or its successor combinations.

The broader point: CagriSema is not the endpoint of obesity-pharmacology innovation, but it's the first major confirmation that the "single GLP-1" era is genuinely over and the future is multi-mechanism combinations. The next decade of weight-loss medicine will be about which combinations work best for which patients — not which single drug is most effective.

The honest read

CagriSema is the strongest confirmation to date that combining non-overlapping satiety mechanisms produces meaningfully better weight loss than activating either pathway alone — and that the side-effect penalty of combination doesn't substantially exceed what monotherapy at maximum doses produces. The roughly 22% mean weight loss in REIMAGINE 1 sits comfortably above semaglutide-alone numbers and within striking distance of tirzepatide and retatrutide outcomes, establishing CagriSema as one of the major options in the next-generation obesity pharmacology landscape.

For most users seeking the maximum-evidence-based path to substantial weight loss, current options (semaglutide, tirzepatide) remain appropriate while CagriSema works through regulatory approval. For users following the obesity-pharmacology pipeline as researchers or self-experimenters, the REIMAGINE 1 results are the most significant data point of 2026 in this space — and the implications for how the field thinks about receptor-combination strategies will continue to play out over the next several years.